Primary non-Hodgkin lymphoma of breast is a rare pathology, representing 0.5% of malignant breast tumors. We report a case of 52 year old female presenting with a large painful mass in left breast with ipsilateral axillary lymph node diagnosed on fine needle aspiration cytology as non-Hodgkin's lymphoma. Breast lymphoma should be differentiated from other breast malignancies because of the differences in their treatment modalities. When breast lymphoma presents as a lump with axillary node, it clinically mimics breast carcinoma. Ultrasonogram and mammogram shows no characteristic features that can distinguish it from other breast malignancy. In such cases, FNAC becomes an important diagnostic tool that can differentiate PBL from other breast malignancy and avoid unnecessary surgery.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520046 | PMC |
| http://dx.doi.org/10.4103/0970-9371.160570 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Wild-Type p53 Regulates Apoptosis of Human Breast Cancer Cells.
Discov Med
December 2024
Department of Breast Surgery, Jiujiang Maternal and Child Health Hospital, 332000 Jiujiang, Jiangxi, China.
Background: The tumor suppressor wild-type p53 is known for its role in inducing apoptosis in tumor cells. This study investigated the relationship between wild-type p53 and protein phosphatase 1 (PP1) and caspase in promoting apoptosis of breast cancer cells.
Methods: Human breast cancer cell lines MCF-7 and MDA-MB-231 obtained from the American Type Culture Collection were used in this study.
Proliferative Myositis of the Breast in a Patient with Contralateral Phyllodes Tumor: A Unique Pseudomalignant Lesion.
Ann Ital Chir
December 2024
Department of Pathology, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, 34147 İstanbul, Türkiye.
Aim: We report a case of proliferative myositis (PM) of the breast, which is the second reported in the English literature.
Case Presentation: A 49-year-old woman underwent surgery due to a fibroadenoma in the right and phyllodes tumor in the left breast. One month after these surgeries, a right breast mass rapidly grew at the surgical site, and biopsy did not provide a diagnosis.
Case report: Therapeutic response to lorlatinib in advanced large-cell neuroendocrine carcinoma of the lung and breast cancer: a heterochronous double malignancy perspective.
Front Pharmacol
December 2024
Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Article Synopsis
- Driver mutations in tyrosine kinases like ALK are important in non-small cell lung cancer but uncommon in large cell neuroendocrine carcinoma (LCNEC).
- A 55-year-old woman with a history of breast cancer developed advanced LCNEC 10 years later, exhibiting multiple brain metastases and testing positive for the ALK fusion gene, leading to treatment with lorlatinib.
- The patient showed a significant tumor reduction after 6 weeks of lorlatinib therapy, indicating that ALK-positive advanced LCNEC might respond well to this treatment, especially for brain metastases.
Evolution of breast cancer management after mediastinal hodgkin lymphoma: Towards a breast- conserving approach.
Eur J Surg Oncol
December 2024
Department of Radiation Oncology, Institut Curie, Paris, France. Electronic address:
Purpose: To analyse the clinical and histological characteristics of breast cancers (BC) occurring after Hodgkin lymphoma (HL), as well as their outcome with particular attention to the effectiveness and safety of breast-conservative surgery with radiation therapy (RT).
Materials And Methods: This is a retrospective study of 218 patients who developed stage 0 to III BC after treatment for mediastinal HL between 1951 and 2022. Comprehensive demographic, clinical, and therapeutic data were collected for HL and BC, as well as survival and locoregional control.
DLBCL cells with ferroptosis morphology can be detected with a deep convolutional neural network.
Biomed Pharmacother
December 2024
Medical Research Center, Oulu University Hospital, Oulu, Finland; Department of Internal Medicine, Länsi-Pohja Central Hospital, Kemi, Finland; Biomedicine and Internal Medicine Research Unit, University of Oulu, Oulu, Finland.
It has been demonstrated that diffuse large B-cell lymphoma (DLBCL) is especially sensitive to ferroptosis. Currently, confirming the presence of ferroptosis requires flow cytometry, which is a time consuming and labor-intensive task. Blistering of the cell membrane has been shown to be a ferroptosis-specific morphological change.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!